Technology Bundle ID
TAB-2635

Dipicolylamine-based Nanoparticles for Delivery of Ligands

Applications
Therapeutics
Linked ID
E-066-2012-0
Lead Inventors
Xiaoyuan Chen (NIBIB)
Co-Inventors
Ki Young Choi (NIBIB)
Seulki Lee (NIBIB)
Development Status
  • Early-stage
  • In vivo data available (animal)
ICs
NIBIB
Many potential nucleic acid therapeutics have not transitioned from the research laboratory to clinical application in large part because delivery technologies for these therapies are not effective. Most nucleic acid delivery technologies are lipid-based or positively charged and require chemical or physical conjugation with the nucleic acid. These delivery systems are often therapeutically unacceptable due to toxicity or immune system reactivity. The present technology is a nanoparticle complex, containing a polymer substrate, such as a hyaluronic acid, and Zn2+-dipicolylamine (Zn-DPA), that associates selectively with the nucleic acid phosphodiester groups. This complex functions as a simple, easy to scale-up, cost effective, low toxicity delivery system for potential nucleic acid therapeutics, such as siRNA molecules. It may also be capable of co-delivering other small molecule drugs.
Commercial Applications
  • Drug delivery
  • Gene therapy
Competitive Advantages
  • Efficient
  • Easy to scale-up
  • Cost effective
  • Low toxicity

Request More Info

Licensing Contact: